ResMed Leads or Sponsors 18 Studies Presented at ATS 2018 International Conference
Studies feature an updated global prevalence of sleep apnea, connected health’s role in increasing therapy adherence, and the economic benefits of an emerging home treatment for COPD

SAN DIEGO – May 23, 2018 – ResMed (NYSE: RMD, ASX: RMD) played a lead role at the ATS 2018 International Conference, hosted by the American Thoracic Society, presenting or sponsoring 18 studies related to sleep apnea and chronic obstructive pulmonary disease (COPD).

Together, the studies updated the prevalence of these diseases – more than 1 billion people combined – and the effectiveness of certain treatments and patient management practices. The abstracts presented include:

Sleep apnea: Prevalence

Sleep apnea: Improving adherence to positive airway pressure (PAP) therapy; benefits of PAP

  • Real World PAP Adherence: Results from a Big Data Approach in More than Two Million Patients (press release) (abstract)
  • Positive Airway Pressure (PAP) Therapy Compliance on a Resupply Program: A Retrospective Analysis (press release) (abstract)
  • A Retrospective Analysis of Bilevel Rescue on Positive Airway Pressure (PAP) Therapy Adherence for Non-Compliant OSA Patients (abstract)
  • Long-term Mortality in Sleep Apnea (SA) Patients Treated with Positive Airway Pressure (PAP) Therapy: Analysis of a Large German Healthcare Database (abstract)

Sleep apnea: Treating patients with comorbidities

  • Morbidity and Mortality of Chronic Heart Failure (CHF) Patients with Central Sleep Apnea (CSA) Treated by Adaptive Servoventilation (ASV): Interim Results of FACE Cohort Study (abstract)
  • Positive Airway Pressure Therapy in Patient Admitted for Acute Heart Failure with Pulmonary Hypertension and Obstructive Sleep Apnea Significantly Reduces Pulmonary Pressures (abstract)

COPD: Economic benefits of adding home NIV (non-invasive ventilation) to home oxygen

  • Cost Effectiveness of Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Hypercapnic Respiratory Failure Following an Acute Exacerbation of COPD in the United Kingdom (UK) – with a separate U.S. health economic analysis of the same study (press release) (UK abstract) (U.S. analysis)

COPD: Prevalence and detection

  • Prevalence of Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) – Preliminary Data from the Homevent Registry (abstract)
  • Daily Measurements of Nocturnal Respiratory Rate Variability May Predict COPD Exacerbations (abstract)
  • Combining non-contact nocturnal respiratory monitoring with respiratory symptom characterization to enhance early detection of COPD exacerbation (abstract)

For details or interview requests related to any of these studies, please email

About ResMed

ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries.


MEDIA: Jayme Rubenstein, 858.836.6798, | INVESTORS: David Pendarvis, 858.836.5000,
Media contacts - Bottom Blue - All Interior Pages

Media contact

Jayme Rubenstein
(858) 836-6798


Receive ResMed news releases when they publish.


ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages